Filing Flows › Eton Pharmaceuticals (ETON) › Guidance & outlook
Eton Pharmaceuticals (ETON) guidance and outlook
Eton Pharmaceuticals (ETON) raised its guidance on Nov 5, 2026: Revenue $175M for FY2026; EBITDA +40% for FY2026; EBITDA margin 35% for FY2026; Gross margin 70% for FY2026. Eton Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $175M | raised |
| EBITDA | FY2026 | +40% | raised |
| EBITDA margin | FY2026 | 35% | reaffirmed |
| Gross margin | FY2026 | 70% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We maintain an established non-GAAP policy that guides the determination of what costs or gains will be included in non-GAAP adjustments.
- Milestone Payments – If a commercial contract arrangement includes development milestone payments, we will evaluate whether the milestone conditions have been achieved and if it is probable that a significant revenue reversal would not occur before recognizing the associated revenue.
- Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the…
- Significant Financing Component – In determining the transaction price, we will adjust consideration for the effects of the time value of money if the expected period between payment by the licensees and the transfer of the promised goods or services to the licensees will be more than one year.
- This allocation requires management to make significant estimates and assumptions, including the selection of valuation methodologies, discount rates, projected cash flows, and useful lives of acquired assets.
- Expected volatilities are based on our historical volatility subsequent to our IPO, which we believe represents the most accurate basis for estimating expected future volatility.
Eton Pharmaceuticals' latest quarter
Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%, net earnings $35.2M, operating cash flow $35.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Eton Pharmaceuticals raise or lower its guidance?
Eton Pharmaceuticals (ETON) raised its guidance on Nov 5, 2026: Revenue $175M for FY2026; EBITDA +40% for FY2026; EBITDA margin 35% for FY2026; Gross margin 70% for FY2026.
What does Eton Pharmaceuticals expect?
We maintain an established non-GAAP policy that guides the determination of what costs or gains will be included in non-GAAP adjustments. Milestone Payments – If a commercial contract arrangement includes development milestone payments, we will evaluate whether the milestone conditions have been achieved and if it is probable that a significant revenue reversal would not occur before recognizing the associated revenue. Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship a
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.